Lastly, the therapeutic landscape, focusing on agents with proven renal benefits, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is reviewed, with evaluating the promise of natural products as multi-target interventions.<h4>Conclusion</h4>Inflammation in DKD is driven by an intricate network of local and systemic factors. This evidence concerns the gene GLP1R and diabetic kidney disease.